Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 67/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed with results

Key Signals

67% success

Data Visualizations

Phase Distribution

2Total

P 3 (2)

Trial Status

Completed2

Unknown1

Terminated1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT02388659Completed

Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas

NCT02731521Completed

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

NCT00897377Phase 3TerminatedPrimary

Treatment Strategy for Low-grade Gliomas

NCT01655927Phase 3Unknown

Efficacy of Tranexamic Acid in Brain Tumor Resections

Showing all 4 trials

Astrocytomas